Galapagos

Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

-- Proposal of one-tier board structure & appointment of three new directors -- Mechelen, Belgium; 24 March 2022, 2 1 .01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) published its annual report for the financial year 202 1 and announces extra ordinary and annual shareholders' meetings to be held sequentially on Tuesday 26 April 2022 at 1:00 p.m. (CET) and 2:00 p.m. (CET) , respectively, at the registered office of the C ompany .

Galapagos publishes 2021 annual report and announces extraordinary and annual shareholders' meetings

KRAKOW, Poland, March 15, 2022 /PRNewswire/ -- Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, today reported financial results for the fourth quarter and the full year ended December 31, 2021, and provided a corporate update. "Over the recent months, we continued to advance our promising oncology pipeline, strengthened our management team, and granted an exclusive, royalty-bearing license to our partner Galapagos", said Pawel Przewiezlikowski, CEO of Ryvu Therapeutics.

Ryvu Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q4 2021 Results - Earnings Call Transcript

Galapagos has failed to prove the mettle of its R&D pipeline in most of the programs it ran.

Galapagos: A History Of Disruptive Failures

Mechelen, Belgium; 2 February 2022, 22.01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) will present d ata at the European Crohn's and Colitis Organization (ECCO) annual congress taking place 16-19 February 2022. Nine oral and poster presentations will be showcased, includ ing four new analyses from the phase 3 SELECTION and SELECTION long term extension (LTE) studies. These are part of the clinical program assessing the efficacy and safety of Jyseleca (filgotinib), an oral, once-daily, JAK1 preferential inhibitor, for the treatment of patients with moderately to severely active ulcerative colitis ( UC ) who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent . In addition, insights from patients participating in a European real-world survey on the disease burden of UC will be present ed.

Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn's and Colitis Organization (ECCO) annual congress

A high-profile healthcare industry executive has been tapped as the company's new CEO.

Why Galapagos Trounced the Market Today

Belgian drugmaker Galapagos NV on Wednesday named former Johnson & Johnson senior executive Paul Stoffels as its chief executive officer, effective April 1.

Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO

Mechelen, Belgium; 26 January 2022, 22 .40  CET; regulated information – Galapagos   NV (Euronext & NASDAQ: GLPG) announced today that its supervisory b oard created 1,000,000 subscription rights under a new subscription right plan for the benefit of a member of the personnel of the Company .

Galapagos creates new subscription right plan

Succeeds current Chief Executive Officer and co-founder Onno van de Stolpe, following planned retirement

Galapagos appoints Paul Stoffels as Chief Executive Officer

Mechelen, Belgium; 6 January 2022, 15.30 CET – Galapagos NV (Euronext & NASDAQ: GLPG) will participate in the 40 th A nnual J.P. Morgan Healthcare Conference on January 10-13 , 20 22.

Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference

Galapagos is in the midst of a transformation process that is expected to result in a completely different company by 2023. Galapagos has over $5.5 billion in cash, an approved drug and a broad pipeline with a market capitalization of only $3.2 billion.

Galapagos: The Investment Thesis Is More Appealing Than Ever

Mechelen, Belgium; 22 November 2021 , 22. 01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) announces completion of recruitment in the MANGROVE Phase 2 trial with investigational CFTR inhibitor GLPG2737 in patients with autosomal dominant polycystic kidney disease (ADPKD).

Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease

Galapagos NV's (GLPG) CEO Onno van de Stolpe on Q3 2021 Results - Earnings Call Transcript

Webcast presentation tomorrow , 5 November 202 1 , at 1 3 .00 CET / 8 AM ET, www.glpg.com , +32 2 793 38 47 , code 4987105

Galapagos reports commercial and operational progress at Q3 financial results

Galapagos (GLPG) finishes enrollment in phase III study evaluating filgotinib for Crohn's Disease. The company also assumes sole responsibility for the DIVERSITY study.

Galapagos (GLPG) Concludes Enrollment in Crohn's Disease Study

Galapagos NV (NASDAQ: GLPG) announced results of two post-hoc analyses from the SELECTION and SELECTION LTE studies of filgotinib for active ulcerative colitis (UC).  The analyses showed clinical benefits of continued dosing with filgotinib 200mg, an oral once-daily JAK1 preferential inhibitor, in patients who did not respond at week 10.

Galapagos' Filgotinib Shows Clinical Benefit In Ulcerative Colitis Non-Responding Patients

Mechelen, Belgium ; 4 October 2021, 22.01 CET ; Galapagos NV (Euronext & NASDAQ: GLPG) today announce d results of two post-hoc analyses from the SELECTION and SELECTION LTE studies , which are part of the investigational clinical program for filgotinib , for the tre atment of patients with moderately to severely active UC. These a nalyses showed clinical benefits of continued dosing with filgotinib 200mg , an oral once-daily JAK1 preferential inhibitor , in patients who did not respond at week 10 . S eparately , HRQoL benefits of filgotinib 200mg treatment versus placebo , in patients with UC were shown . These data will be p resented at the UEGW virtual 2021 congress (3 – 5 October) .

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress

Galapagos NV (NASDAQ: GLPG) has randomized the last patient into the DIVERSITY Phase 3 study of filgotinib in the induction and maintenance of remission in patients with Crohn's Disease (CD). The DIVERSITY study enrolled 1,374 participants.

Galapagos Assumes Responsibility Of Late-Stage Filgotinib Trial In Crohn's Disease

Mechelen, Belgium; 4 October  2021, 07.01  CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced randomization of the last patient in to the multi-cent er , global DIVERSITY Phase 3 study . The study is designed to evaluate the efficacy and safety of filgotinib, a JAK1 preferential inhibitor, in the induction and maintenance of remission in patients w ith Crohn's Disease (CD) .

Galapagos announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn's Disease

Mechelen, Belgium ; 17 September 2021 ; 13.15 CET ; Galapagos NV (Euronext & Nasdaq: GLPG) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca ® ( filgotinib ), a once - daily, oral, JAK1 preferential inhibitor for the treatment of adult patients with moderately to sever ely active ulcerative colitis (UC) who have ha d an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent. F ollowing this positive opinion , a final decision from the European C ommission is expected later this year .

GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

When any team underperforms, it's usually the manager or coach who gets the axe. The same often holds true in the corporate world.

Galapagos Says New CEO Will Have Strong Science Background

After 22 years at the helm of Galapagos NV (NASDAQ: GLPG), chief executive Onno van de Stolpe has decided it is time to retire and hand the reins to new leadership. He will stay in his role until a successor is found.

Galapagos' Long-Serving CEO Onno Van De Stolpe To Exit After R&D Setbacks

Galapagos announces planned retirement of CEO

Galapagos NV (GLPG) CEO Onno van de Stolpe on Q2 2021 Results - Earnings Call Transcript

Webcast presentation tomorrow , 6 August 202 1 , at 14.00 CET / 8 AM ET, www.glpg.com , +32 2 793 38 47 , code 8245 817

News for Galapagos Stock (GLPG)